Skip to content

Sample Page

$C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population$

Author: C4 Therapeutics, Inc.

Posted Date:

June 11, 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics, Inc.

June 11, 2026
C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics, Inc.

May 20, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc.

May 18, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics, Inc.

May 12, 2026
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics, Inc.

April 9, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc.

March 25, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc.

March 9, 2026
C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics, Inc.

February 23, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc.

February 23, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc.

February 9, 2026

1 2